Our Medimmune rep was in our office today telling us that the AAP has
issued revised guidelines for the use of Synagis that drastically
curtails who will receive the drug--revisions supposed based upon cost
analysis rather than new efficacy findings. I've been Googling, etc. and
haven't found anything yet.
Any of you AAP members know about this? If you find a link to the
official revised guidelines, please forward.
Gary Mirkin, MD